# ETOP IBCSG Partners Foundation

Source: https://onco.cc/companies/etop-ibcsg/  
OnCo record `etop-ibcsg` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The Bern-based foundation that unites the International Breast Cancer Study Group (SOFT, TEXT, POSITIVE) and the European Thoracic Oncology Platform.

## Summary

The International Breast Cancer Study Group began in 1977 as the Ludwig Breast Cancer Study Group and has run academic breast cancer trials for almost fifty years, including SOFT and TEXT (ovarian function suppression in premenopausal women), the POSITIVE study of pausing endocrine therapy to attempt pregnancy, and the early HER2-positive and elderly trials. ETOP was founded in 2009 to run academic thoracic oncology trials across Europe, including BEAT-meso in mesothelioma and the SPLENDOUR and ETOP Lungscape biomarker programmes. In 2022 the two merged into the ETOP IBCSG Partners Foundation, sharing a coordinating centre in Bern and a statistical centre. Both arms partner with the Breast International Group, Breast Cancer Trials and the US cooperative groups.

## Fields

- Kind: Company
- Last checked: 2026-09-09
- Also known as: ETOP; European Thoracic Oncology Platform; IBCSG; International Breast Cancer Study Group; Ludwig Breast Cancer Study Group
- Tags: cooperative-group
- HQ: Bern
- Type: cooperative-group
- Website: https://www.ibcsg.org

## Notes

- SOFT / TEXT (IBCSG 24-02, 25-02)
- POSITIVE (pregnancy after endocrine therapy)
- BEAT-meso and thoracic trials (ETOP)
- Lungscape biomarker cohort

## Sources

- IBCSG: https://www.ibcsg.org
- ETOP: https://www.etop-eu.org

## Connected records

- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/)
- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Hormonal Therapy](https://onco.cc/fronts/hormonal/)
- technologies: [Endocrine therapy (SERMs, AIs, SERDs)](https://onco.cc/technologies/endocrine-therapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- companies: [Alliance for Clinical Trials in Oncology](https://onco.cc/companies/alliance-oncology/), [Breast Cancer Trials](https://onco.cc/companies/breast-cancer-trials/), [Breast International Group (BIG)](https://onco.cc/companies/big/), [Intergroupe Francophone de Cancérologie Thoracique](https://onco.cc/companies/ifct/)
- trials: [BEAT-meso (ETOP 13-18)](https://onco.cc/trials/beat-meso/), [SOFT & TEXT](https://onco.cc/trials/soft-text/)
- people: [Rolf A. Stahel](https://onco.cc/people/rolf-stahel/), [Solange Peters](https://onco.cc/people/solange-peters/)
- journals: [Lung cancer](https://onco.cc/journals/lung-cancer-journal/)

---
JSON: https://onco.cc/api/v1/entities/etop-ibcsg.json